| |
Breakthrough for HCV research: in vitro HCV replication
|
| |
| |
Nature Reviews Drug Discovery 4, 629 (August 2005)
Susan Jones
Hepatitis C virus (HCV) afflicts more than 170 million people worldwide but until now HCV research has been severely hampered by the inability to produce infectious virus in cell culture. In a major breakthrough, three groups have reported the replication of full-length HCV clones in vitro, paving the way for the development of effective antiviral therapies and vaccines.
HCV primarily infects hepatocytes and causes hepatitis, cirrhosis of the liver and hepatocellular carcinoma. There is no vaccine, and drug treatments are costly and have poor efficacy. The absence of a small-animal model and a cell-culture system for HCV have been obstacles to studying this virus, and researchers have relied on studying infections in humans and chimpanzees.
In the past 5 years, the development of in vitro HCV replicon systems has enabled viral molecular biology and virus-host interactions to be probed. Such systems use genomic and subgenomic clones that are transfected into hepatocyte cell lines. The main disadvantage of these systems is that the RNAs cannot replicate in vitro without acquiring adaptive mutations, nor do these systems produce infectious virions, so their relevance to the biology of wild-type infectious HCV isolates is questionable.
Three groups set out to develop faithful in vitro replication systems for HCV. These studies build upon very recent advances: in the past 2 years, the Wakita group developed an in vitro system that replicates a subgenomic RNA that has not acquired any adaptive mutations, which formed the basis for the studies just published. All three groups used hepatocyte cell lines and, importantly, all of the full-length replicons were either the JFH-1 HCV strain that was previously isolated from a fulminant-hepatitis patient by Wakita's group or a chimaera based on that strain. None of the full-length RNA clones that were used in these studies contained adaptive mutations, which is crucial, because the Bartenschlager group had shown that these mutations interfere with virus production and infectivity in vivo. Therefore, the systems are representative of the wild-type HCV infection cycle. In all three studies, monitoring of viral RNA production by PCR, protein production by antibody labelling and classic dilution and infection studies were used to quantify RNA replication.
The different studies have common features. First, all of the in vitro systems replicate the full-length viral RNA and transfected cells produce virions - evidence of a complete virus life-cycle. Second, viruses produced in vitro can be propagated efficiently using cell passage. Third, all three groups showed that the biophysical properties of the virions that are secreted by transfected cells are comparable to virions produced in chimpanzees infected with wild-type HCV. Finally, Wakita et al. used intravenous inoculation with in vitro-produced virus suspensions to prove that the in vitro-produced virus is infectious in chimpanzees. All three groups showed that antibodies against virus proteins neutralized the infectivity of virus that was produced in vitro. Furthermore, Wakita et al. and Zhong et al. blocked a putative cellular receptor, CD81, using anti-CD81 antibody, whereas Lindenbach et al. blocked the same receptor with a soluble recombinant CD81 fragment and prevented in vitro-produced virus from infecting Huh-7.5 cells. The development of these tissue-culture systems should accelerate the pace of hepatitis research.
References and links
ORIGINAL RESEARCH PAPERS
Wakita, W. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med. 13 June 2005
Lindenbach, B. D. et al. Complete replication of hepatitis C virus in cell culture. Science 09 June 2005
Zhong, J. et al. Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 06 June 2005
|
|
| |
| |
|
|
|
